Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative
| Autor: | C. Chaib, Geoff Hall, W. Sopwith, S. Cheeseman, John R. Penrod, M. Snee, M. Thompson, L. Lacoin, John C O'Donnell, M. Riaz, Melinda Daumont |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Lung Neoplasms medicine.medical_treatment thoracic medicine chemotherapy State Medicine Metastasis 03 medical and health sciences 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung Epidemiology medicine Humans 030212 general & internal medicine Medical prescription Lung cancer Retrospective Studies Chemotherapy Performance status business.industry respiratory tract tumours Medical record General Medicine medicine.disease Prescriptions Oncology 030220 oncology & carcinogenesis Medicine epidemiology business Cohort study |
| Zdroj: | BMJ Open BMJ Open, Vol 11, Iss 5 (2021) |
| ISSN: | 2044-6055 |
| Popis: | ObjectivesTo assess how a decade of developments in systematic anticancer therapy (SACT) for advanced non-small cell lung cancer (NSCLC) affected overall survival (OS) in a large UK University Hospital.DesignReal-world retrospective observational cohort study using existing data recorded in electronic medical records.SettingA large National Health Service (NHS) university teaching hospital serving 800 000 people living in a diverse metropolitan area of the UK.Participants2119 adults diagnosed with advanced NSCLC (tumour, node, metastasis stage IIIB or IV) between 2007 and 2017 at Leeds Teaching Hospitals NHS Trust.Main outcomes and measuresOS following diagnosis and the analysis of factors associated with receiving SACT.ResultsMedian OS for all participants was 2.9 months, increasing for the SACT-treated subcohort from 8.4 months (2007–2012) to 9.1 months (2013–2017) (p=0.02); 1-year OS increased from 33% to 39% over the same period for the SACT-treated group. Median OS for the untreated subcohort was 1.6 months in both time periods. Overall, 30.6% (648/2119) patients received SACT; treatment rates increased from 28.6% (338/1181) in 2007–2012 to 33.0% (310/938) in 2013–2017 (p=0.03). Age and performance status were independent predictors for SACT treatment; advanced age and higher performance status were associated with lower SACT treatment rates.ConclusionAlthough developments in SACT during 2007–2017 correspond to some changes in survival for treated patients with advanced NSCLC, treatment rates remain low and the prognosis for all patients remains poor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|